Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan for COVID-19 Respiratory Failure
NCT04335123Phase 1Completed
- Sponsor
- University of Kansas Medical Center
- Start
- Apr 2020
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of losartan in coronavirus disease 2019 (COVID-19) and respiratory failure, sponsored by University of Kansas Medical Center. Primary endpoint: Treatment-related Adverse Events at 14 days. Started Apr 2020; status: completed.
02
Drugs
losartan
03
Conditions
coronavirus disease 2019 (COVID-19)respiratory failure
Beyond the preview
Go deeper on NCT04335123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04335123.